Calidi Biotherapeutics, Inc. (CLDI): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 16:35 ET
- Event date
- 2026-11-13
- Accession no.
- 0001193125-26-460816
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
Calidi reports third-quarter 2026 results and headcount restructuring
Calidi reported a third-quarter 2026 net loss attributable to common stockholders of $3.6 million, compared to $10.8 million for the third quarter of 2025. It also disclosed a restructuring predominantly through headcount reductions, expected to save $3 million on an annualized basis, and presented preclinical data for CLD-401 and its T-cell engager platform.
- Third-quarter 2026 net loss attributable to common stockholders was $3.6 million, compared to $10.8 million for 2025.
- Cash was $3.9 million and restricted cash was $0.2 million as of September 30, 2026.
- A restructuring executed November 6, 2026, predominantly through headcount reductions, is expected to save $3 million annually.
- An at-the-market registered direct offering closed September 18, 2026, providing $1.2 million in gross proceeds.
earningsrestructuringequity offering
Items reported
- Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed". - Item 7.01: Regulation FD Disclosure
The company is making information public under Regulation FD, which requires broad public disclosure of material information shared with certain market participants. Investor presentations and press releases are common. Like Item 2.02, this information is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | 8-K | cldi-20261113.htm |
| EX-99.1 | EX-99.1 | cldi-ex99_1.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.